The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A modified toxicity probability interval method for dose-finding trials
Open accessAbstract
Background Building on earlier work, the toxicity probability interval (TPI) method, we present a modified TPI (mTPI) design that is calibration-free for phase I trials. Purpose Our goal is to improve the trial conduct and provide more effective designs while maintaining the simplicity of the original TPI design. Methods Like the TPI method, the mTPI consists of a practical dose-finding scheme guided by the posterior inference for a simple Bayesian model. However, the new method proposes improved dose-finding decision rules based on a new statistic, the unit probability mass (UPM). For a given interval and a probability distribution, the UPM is defined as the ratio of the probability mass of the interval to the length of the interval. Results The improvement through the use of the UPM for dose finding is threefold: (1) the mTPI method appears to be safer than the TPI method in that it puts fewer patients on toxic doses; (2) the mTPI method eliminates the need for calibrating two key parameters, which is required in the TPI method and is a known difficult issue; and (3) the mTPI method corresponds to the Bayes rule under a decision theoretic framework and possesses additional desirable large- and small-sample properties. Limitation The proposed method is applicable to dose-finding trials with a binary toxicity endpoint. Conclusion The new method mTPI is essentially calibration free and exhibits improved performance over the TPI method. These features make the mTPI a desirable choice for the design of practical trials. Clinical Trials 2010; 7: 653—663. http://ctj.sagepub.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelman, A., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2003) · doi:10.1201/9780429258480 · Cited by 27,276
Bayes and Empirical Bayes Methods for Data Analysis
(2001) · Technometrics · doi:10.1198/tech.2001.s608 · Cited by 2,098
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Bayes and Empirical Bayes Methods for Data Analysis, Second Edition
Carlin, B., & Louis, T. (2000) · Chapman & Hall/CRC Texts in Statistical Science · doi:10.1201/9781420057669 · Cited by 959
Bayes and Empirical Bayes Methods for Data Analysis.
Leonard, T., Carlin, B. P., & Louis, T. A. (1997) · Biometrics · doi:10.2307/2533126 · Cited by 788
Cancer phase I clinical trials: efficient dose escalation with overdose control
Babb, J., Rogatko, A., & Zacks, S. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9 · Cited by 623
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cheung, Y. K., & Chappell, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.01177.x · Cited by 545
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
Large Sample Methods in Statistics
Sen, P. K., & Singer, J. M. (1993) · Springer eBooks · doi:10.1007/978-1-4899-4491-7 · Cited by 331
Model calibration in the continual reassessment method
Lee, S. M., & Cheung, Y. K. (2009) · Clinical Trials · doi:10.1177/1740774509105076 · Cited by 225
Cited by
Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., Chow, L. Q., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 445
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
(2016) · doi:10.1158/1078-0432.ccr-16-0592 · Cited by 235
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
de Bono, J. S., Fleming, M. T., Wang, J. S., Cathomas, R., Miralles, M. S., Bothos, J., Hinrichs, M. J., Zhang, Q., He, P., Williams, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4528 · Cited by 54
Metadata
- Authors
- Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2010-10-08
- Volume
- 7
- Issue
- 6
- Pages
- 653-663
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2113073012
- Cited by
- 273
- References
- 16
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A modified toxicity probability interval method for dose-finding trials. https://app.cochat.ai/papers/10.1177/1740774510382799
- The paper
- Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials. https://doi.org/10.1177/1740774510382799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.